

Colin Baigent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9506352/publications.pdf>

Version: 2024-02-01

133
papers

40,512
citations

13865

67
h-index

12597

132
g-index

137
all docs

137
docs citations

137
times ranked

38132
citing authors

#	ARTICLE	IF	CITATIONS
1	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 4-13.	4.0	52
2	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European Journal of Preventive Cardiology, 2022, 28, 2030-2037.	1.8	8
3	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 "epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	3.8	27
4	Conventional and Genetic Evidence on the Association between Adiposity and CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 127-137.	6.1	39
5	Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. The Lancet Gastroenterology and Hepatology, 2021, 6, 199-208.	8.1	244
6	The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. Kidney International, 2021, 99, 791-793.	5.2	74
7	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	13.7	414
8	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	7.1	36
9	What is the association of COVID-19 with heart attacks and strokes?. Lancet, The, 2021, 398, 561-563.	13.7	3
10	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	13.7	133
11	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage. JAMA Neurology, 2021, 78, 1179.	9.0	25
12	Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology, The, 2021, 20, 842-853.	10.2	44
13	Relationship between anaemia, coagulation parameters during pregnancy and postpartum haemorrhage at childbirth: a prospective cohort study. BMJ Open, 2021, 11, e050815.	1.9	12
14	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163.	7.1	33
15	Chronic kidney disease, heart failure and neprilysin inhibition. Nephrology Dialysis Transplantation, 2020, 35, 558-564.	0.7	39
16	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
17	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
18	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647

#	ARTICLE	IF	CITATIONS
19	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
20	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
21	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 47-60.	4.5	41
22	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. International Journal of Obesity, 2020, 44, 2256-2266.	3.4	9
23	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. European Heart Journal, 2020, 41, 3336-3342.	2.2	27
24	Questioning statin therapy for older patients – Authors' reply. Lancet, The, 2020, 395, 1832-1833.	13.7	0
25	COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet, The, 2020, 396, 381-389.	13.7	521
26	Clinical trial recommendations for potential Alport syndrome therapies. Kidney International, 2020, 97, 1109-1116.	5.2	7
27	Variability in aspirin efficacy: all in the genes?. European Heart Journal, 2019, 40, 3393-3396.	2.2	3
28	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	13.7	512
29	Role of aspirin in primary prevention of cardiovascular disease. Nature Reviews Cardiology, 2019, 16, 675-686.	13.7	97
30	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet, The, 2019, 393, 2613-2623.	13.7	134
31	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology, The, 2019, 18, 643-652.	10.2	68
32	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	5.2	232
33	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
34	Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. Lancet, The, 2019, 393, 1009-1020.	13.7	119
35	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.7	6
36	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology and Hepatology, 2018, 3, 231-241.	8.1	156

#	ARTICLE	IF	CITATIONS
37	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
38	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , 2018, 93, 1165-1174.	5.2	21
39	The role of lipoprotein (a) in chronic kidney disease. <i>Journal of Lipid Research</i> , 2018, 59, 577-585.	4.2	77
40	Should We Increase GFR with Bardoxolone in Alport Syndrome?. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 357-359.	6.1	33
41	Impact of CKD on Household Income. <i>Kidney International Reports</i> , 2018, 3, 610-618.	0.8	25
42	Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 455-463.	11.4	50
43	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434.	4.7	18
44	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	5.2	32
45	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	2.9	196
46	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	6.1	140
47	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
48	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1529-1539.	27.0	823
49	Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1540-1550.	27.0	510
50	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , 2018, 13, 175-189.	5.9	36
51	Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw095.	0.7	40
52	Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2738-2748.	6.1	19
53	Safety and efficacy of statins – Authors' reply. <i>Lancet, The</i> , 2017, 389, 1099-1100.	13.7	1
54	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322.	2.7	30

#	ARTICLE	IF	CITATIONS
55	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	2.8	140
56	PCSK9 inhibition: a new player in cholesterol-lowering therapies?. Nature Reviews Nephrology, 2017, 13, 450-451.	9.6	3
57	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 546-552.	4.5	41
58	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	3.4	24
59	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1794-1801.	4.5	22
60	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology, 2016, 4, 829-839.	11.4	234
61	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. Stroke, 2016, 47, 2373-2379.	2.0	193
62	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 2016, 388, 2532-2561.	13.7	1,399
63	Diabetes and Cause-Specific Mortality in Mexico City. New England Journal of Medicine, 2016, 375, 1961-1971.	27.0	207
64	Aspirin for Disease Prevention: Public Policy or Personal Choice?. Annals of Internal Medicine, 2016, 164, 846.	3.9	4
65	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	1.9	57
66	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 591-598.	1.9	74
67	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, 2016, 15, 925-933.	10.2	187
68	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	1.9	42
69	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
70	Cholesterol Metabolism and Statin Effectiveness in Hemodialysis Patients –. Journal of the American College of Cardiology, 2015, 65, 2299-2301.	2.8	5
71	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet, 2015, 385, 1397-1405.	13.7	1,112
72	Thrombolysis in acute stroke – Authors' reply. Lancet, 2015, 385, 1396.	13.7	5

#	ARTICLE	IF	CITATIONS
73	Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. American Heart Journal, 2015, 169, 605-612.	2.7	44
74	Neprilysin inhibition in chronic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 738-743.	0.7	80
75	Alteplase for Acute Ischemic Stroke. Stroke, 2015, 46, 746-756.	2.0	74
76	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	1.1	0
77	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	1.3	49
78	Air pollution and traffic noise: do they cause atherosclerosis?. European Heart Journal, 2014, 35, 826-828.	2.2	1
79	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	6.1	142
80	Aspirin in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine, 2014, 370, 1494-1503.	27.0	735
81	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2014, 64, 40-48.	1.9	55
82	Blood pressure lowering and cardiovascular risk – Authors' reply. Lancet, The, 2014, 384, 1746-1747.	13.7	118
83	Misrepresentation of statin safety evidence. Lancet, The, 2014, 384, 1263-1264.	13.7	10
84	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	13.7	1,971
85	Coxibs and traditional NSAIDs for pain relief – Authors' reply. Lancet, The, 2014, 383, 122.	13.7	7
86	Nonsteroidal Anti-Inflammatory Drugs and the Heart. Circulation, 2014, 129, 907-916.	1.6	99
87	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	4.5	19
88	General mechanisms of coagulation and targets of anticoagulants (Section I). Thrombosis and Haemostasis, 2013, 109, 569-579.	3.4	165
89	Randomized Clinical Trials – Removing Unnecessary Obstacles. New England Journal of Medicine, 2013, 369, 1061-1065.	27.0	103
90	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thrombosis and Haemostasis, 2013, 110, 1087-1107.	3.4	347

#	ARTICLE	IF	CITATIONS
91	Statins for people at low risk of cardiovascular disease – Authors' reply. Lancet, The, 2012, 380, 1817-1818.	13.7	127
92	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 59, 1413-1425.	2.8	257
93	Aspirin in primary prevention – good news and bad news. Nature Reviews Cardiology, 2012, 9, 262-263.	13.7	19
94	Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy. PLoS ONE, 2012, 7, e29849.	2.5	270
95	Efficacy and safety of more intensive lowering of LDL cholesterol – Authors' reply. Lancet, The, 2011, 377, 715-716.	13.7	6
96	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	13.7	2,087
97	Benefits of lowering cholesterol in chronic kidney disease – Authors' reply. Lancet, The, 2011, 378, 1377-1378.	13.7	1
98	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. PLoS ONE, 2011, 6, e25920.	2.5	70
99	Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 2011, 32, 2922-2932.	2.2	203
100	Aspirin for asymptomatic atherosclerosis?. Nature Reviews Cardiology, 2010, 7, 306-307.	13.7	3
101	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. American Journal of Kidney Diseases, 2010, 56, 1082-1094.	1.9	144
102	Revascularization versus Medical Therapy for Renal-Artery Stenosis. New England Journal of Medicine, 2009, 361, 1953-1962.	27.0	1,035
103	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, The, 2009, 373, 1849-1860.	13.7	3,100
104	Aspirin in the primary prevention of vascular disease – ATT secretariat's reply. Lancet, The, 2009, 374, 879.	13.7	0
105	Low-Dose Aspirin, Coxibs, and other NSAIDs: A Clinical Mosaic Emerges. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 31-39.	3.4	58
106	Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clinical Trials, 2008, 5, 49-55.	1.6	129
107	Statins and diabetes – Authors' reply. Lancet, The, 2008, 371, 1752.	13.7	160
108	Antiplatelet Drugs. Chest, 2008, 133, 199S-233S.	0.8	478

#	ARTICLE	IF	CITATIONS
109	Sensible guidelines for the conduct of large randomized trials. Clinical Trials, 2008, 5, 38-39.	1.6	51
110	Analyses of Cancer Data from Three Ezetimibe Trials. New England Journal of Medicine, 2008, 359, 1357-1366.	27.0	230
111	B Vitamins for the Prevention of Vascular Disease. JAMA - Journal of the American Medical Association, 2007, 298, 1212.	7.4	16
112	Anticoagulants in heart disease: current status and perspectives. European Heart Journal, 2007, 28, 880-913.	2.2	119
113	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials. Seminars in Dialysis, 2007, 20, 498-503.	1.3	23
114	Efficacy and safety of cholesterol-lowering treatment – Authors' reply. Lancet, The, 2006, 367, 470-471.	13.7	9
115	Statins: are any questions unanswered?. Current Opinion in Lipidology, 2006, 17, 418-425.	2.7	10
116	The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD. American Journal of Kidney Diseases, 2006, 47, 385-395.	1.9	104
117	Which cardiovascular risk factors matter in chronic kidney disease?. Nephrology Dialysis Transplantation, 2006, 22, 9-11.	0.7	18
118	Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 4-5.	3.3	15
119	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases, 2005, 45, 473-484.	1.9	184
120	Low-Dose Aspirin for the Prevention of Atherothrombosis. New England Journal of Medicine, 2005, 353, 2373-2383.	27.0	1,053
121	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. European Heart Journal, 2004, 25, 166-181.	2.2	334
122	Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. American Journal of Kidney Diseases, 2004, 43, 244-253.	1.9	272
123	Review of The struggle for life: A psychological perspective of kidney disease and transplantation. American Journal of Kidney Diseases, 2004, 44, 382.	1.9	0
124	Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Current Opinion in Nephrology and Hypertension, 2004, 13, 601-605.	2.0	15
125	Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. Arthritis and Rheumatism, 2003, 48, 12-20.	6.7	110
126	Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men. Journal of the American Society of Nephrology: JASN, 2003, 14, 2084-2091.	6.1	352

#	ARTICLE	IF	CITATIONS
127	Benefit of aspirin plus angiotensin-converting enzyme inhibitor. Journal of the American College of Cardiology, 2001, 37, 1474-1475.	2.8	0
128	Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. American Journal of Kidney Diseases, 2001, 38, 537-546.	1.9	97
129	Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?. Nephrology Dialysis Transplantation, 2000, 15, 1118-1119.	0.7	22
130	Premature cardiovascular disease in chronic renal failure. Lancet, The, 2000, 356, 147-152.	13.7	502
131	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Journal of the American College of Cardiology, 2000, 35, 1801-1807.	2.8	156
132	Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. New England Journal of Medicine, 1997, 336, 847-860.	27.0	308
133	Clopidogrel reduced stroke, MI, and vascular death compared with aspirin. ACP Journal Club, 1997, 126, 59.	0.1	1